This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Parkinson disease파킨슨병

Contents and key points
ItemDetails
A. Classification codesICD-10: G20 (Parkinson disease) | Special Copayment Reduction: V124 (severe intractable disease, 5 years)
B. SynonymsIdiopathic Parkinsonism, primary Parkinsonism, hemiparkinsonism, paralysis agitans, Parkinsonism NOS
C. Adult onsetPossibility of adult onset is very high — occurs mainly at age 60 or older (prevalence 1–2%), with early onset at age 50 or younger (EOPD) accounting for about 5–10% of all cases. Occurrence is concentrated in adulthood (age 50 or older).
1. History1817 James Parkinson's "An Essay on the Shaking Palsy" → refinement of the clinical description by Charcot → 1960s discovery of the dopamine deficiency mechanism (Ehringer·Hornykiewicz) → the levodopa treatment era → discovery of alpha-synuclein and Lewy bodies → identification of genes for hereditary Parkinson disease → 2020s expansion of GBA1 clinical research
2. CausesMostly sporadic (combined environmental + genetic); monogenic: LRRK2, SNCA, PRKN, PINK1, DJ-1, GBA1; risk factors: older age, male sex, pesticide/herbicide exposure, MPTP; protective factors: caffeine, smoking (paradoxical), exercise
3. GeneticsLRRK2 (12q12) autosomal dominant; SNCA (4q21) autosomal dominant; PRKN (6q26) autosomal recessive (early onset); PINK1 (1p36) autosomal recessive; GBA1 (1q22) risk factor variants (heterozygous)
4. General epidemiologyPrevalence about 1–2% at age 60 or older; about 10 million people worldwide; prevalence in Korea about 200/100,000 (age 60 or older); annual incidence 8–18/100,000; about 1.5 times more common in men
5. PathophysiologySelective loss of dopaminergic neurons in the substantia nigra → reduced striatal dopamine → dysfunction of the basal ganglia motor control circuits; Lewy body (alpha-synuclein aggregate) formation; mitochondrial dysfunction; oxidative stress; stepwise progression of Braak pathology
6. SymptomsMotor symptoms: resting tremor (4-6 Hz), rigidity, bradykinesia, postural instability; non-motor symptoms: loss of smell, REM sleep behavior disorder, constipation, depression, cognitive decline, autonomic dysfunction
7. SignsResting tremor (about 70%), cogwheel rigidity, bradykinesia (micrographia, hypophonia, masked face), stooped posture, festinating gait, Myerson's sign, orthostatic hypotension
8. ScreeningOlfactory function testing (University of Pennsylvania Smell Identification Test), Parkinson disease risk questionnaires; neurological follow-up of high-risk families (LRRK2·GBA1 carriers); screening for REM sleep behavior disorder
9. DiagnosisMDS (Movement Disorder Society) clinical diagnostic criteria (2015); confirmation of levodopa response; brain MRI (structural differentiation); DAT-SPECT (dopamine transporter imaging); olfactory testing; autonomic testing
10. TreatmentLevodopa/carbidopa (standard treatment); dopamine agonists (pramipexole, ropinirole); MAO-B inhibitors (rasagiline, selegiline); COMT inhibitors; deep brain stimulation (DBS, from the middle stage onward); rehabilitation therapy; gene and cell therapy (clinical research stage)
11. PrognosisVaries between individuals; progressive chronic course; wheelchair dependence on average 10–15 years after diagnosis; non-motor symptoms (dementia, autonomic failure, falls) have a major impact on quality of life and mortality
12. PreventionMinimize exposure to pesticides and insecticides; regular aerobic exercise (neuroprotective effect proposed); caffeine intake (epidemiologically associated with protection); monitoring of the genetic high-risk group (GBA1·LRRK2 carriers)
13. ReferencesPostuma RB et al. Mov Disord 2015 and 9 other papers

1. History

The history of Parkinson disease formally begins with the monograph "An Essay on the Shaking Palsy" published in 1817 by the English physician James Parkinson. Parkinson observed 6 patients and described features such as resting tremor, stooped posture, festinating gait and preserved muscle strength, proposing this as an independent clinical entity. However, owing to the limits of clinical description at the time, the paper received little attention for decades.

In the late 19th century, the French neuroscientist Jean-Martin Charcot classified the condition described by Parkinson more precisely and expanded its clinical features. Charcot described resting tremor and rigidity separately from bradykinesia and named the disease "Parkinson's disease" after his teacher Parkinson. Without Charcot's contribution, it would have been difficult to establish the modern concept of Parkinson disease.

The most decisive discovery, made in the mid-20th century, was the elucidation of the dopamine deficiency mechanism. In 1960 Arvid Carlsson showed that dopamine functions as a neurotransmitter in the brain, and in the same year Oleh Hornykiewicz and Herbert Ehringer confirmed that dopamine is markedly reduced in the substantia nigra of the brains of patients with Parkinson disease. Carlsson received the 2000 Nobel Prize in Physiology or Medicine for this research. This discovery led to the development of levodopa (L-DOPA) therapy. In 1967 George Cotzias published clinical results showing dramatic improvement of Parkinson disease symptoms with high-dose oral levodopa, opening the era of levodopa, which remains the standard treatment to this day.

In 1997 Michele Polymeropoulos and colleagues first identified variants in the alpha-synuclein (α-synuclein) gene (SNCA) in a family with familial Parkinson disease. In the same year, Spillantini and Goedert showed that alpha-synuclein is the main component of the Lewy body, the characteristic pathological finding of Parkinson disease, establishing alpha-synuclein aggregation as the core pathology of Parkinson disease. Subsequently, as numerous Parkinson disease-associated genes such as LRRK2, PRKN, PINK1 and DJ-1 were identified, the molecular genetics of hereditary Parkinson disease developed rapidly.

In 2003 Braak and colleagues proposed the hypothesis of stepwise progression of Parkinson disease pathology from the brainstem to the cortex (Braak staging), establishing the concept that non-motor prodromal symptoms (loss of smell, constipation, REM sleep behavior disorder) appear years to decades before motor symptoms. Recently, the "gut-brain axis" hypothesis, which holds that alpha-synuclein pathology beginning in the gut spreads to the brain via the vagus nerve, has been proposed and is being actively studied.


2. Causes

Parkinson disease is mostly multifactorial, arising from a combination of genetic predisposition and environmental factors. About 85–90% of all patients are sporadic, and about 10–15% have familial forms explained by single-gene variants.

Environmental risk factors

Exposure to pesticides and insecticides (rotenone, paraquat, organophosphates) has been shown in several epidemiological studies to increase the risk of Parkinson disease 2- to 4-fold. The increase in risk is particularly pronounced among agricultural workers. The 1982 incident in which drug users exposed to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) developed acute parkinsonism showed that dopaminergic neurons of the substantia nigra are selectively vulnerable to toxins. Chronic exposure to heavy metals (manganese, lead, mercury), head trauma and exposure to aliphatic solvents have also been proposed as risk factors.

Protective factors (paradoxical)

Caffeine (coffee) intake and smoking are epidemiologically observed to lower the risk of Parkinson disease. The adenosine A2A receptor-blocking effect of caffeine may be associated with protection of dopaminergic neurons. Regular aerobic exercise and an antioxidant diet are also proposed to have protective effects. However, a causal relationship for the protective effect of smoking is difficult to prove because of possibilities such as selection bias (healthier people smoke more).

Genetic causes

Familial Parkinson disease due to single-gene variants: LRRK2 (autosomal dominant, G2019S variant most common), SNCA (autosomal dominant; duplications or triplications give a phenotype similar to sporadic disease), PRKN (parkin) (autosomal recessive, early onset), PINK1 (autosomal recessive, early onset), DJ-1 (PARK7) (autosomal recessive), ATP13A2 (PARK9) (autosomal recessive). As a risk gene, heterozygous variants of GBA1 (glucocerebrosidase, the gene causing Gaucher disease) raise the risk of Parkinson disease about 4- to 8-fold, and GBA1 variants are found in about 5–15% of all Parkinson disease.


3. Genetics

The major genes associated with Parkinson disease are as follows.

LRRK2 (leucine-rich repeat kinase 2)

Located on chromosome 12 (12q12) and inherited in an autosomal dominant manner. The G2019S variant is the single-gene variant most commonly found in patients with Parkinson disease, with high frequencies in Ashkenazi Jews (about 15–40%) and North African Arabs (about 30–40%). It is found in about 1–2% of general Caucasian patients with Parkinson disease and is rare in Koreans. The clinical phenotype is similar to sporadic Parkinson disease, with a good levodopa response. Penetrance is age-dependent: about 30% at age 70 and about 70% at age 80.

SNCA (alpha-synuclein)

Located on chromosome 4 (4q21); autosomal dominant. Point variants (A53T, A30P, E46K) and gene duplications/triplications cause familial Parkinson disease. SNCA duplication shows a phenotype similar to sporadic Parkinson disease, while triplication shows a more severe course (dementia, autonomic failure). Alpha-synuclein protein is the main component of Lewy bodies, and inhibiting its aggregation is currently a major target of neuroprotective therapy.

PRKN (parkin), PINK1, DJ-1

All are autosomal recessive and associated with early-onset Parkinson disease (Early-onset PD, EOPD). PRKN (6q26) is involved in the ubiquitin-proteasome pathway, and when mutated, impaired mitophagy leads to mitochondrial dysfunction. PINK1 (1p36) senses the mitochondrial membrane potential and cooperates with parkin to selectively remove damaged mitochondria. Parkinson disease with PINK1·PRKN variants sometimes shows pure nigral degeneration without Lewy bodies.

GBA1 (glucocerebrosidase)

Located on chromosome 1 (1q22); heterozygous variants (p.N370S, p.L444P, etc.) act as risk factors for Parkinson disease. Parkinson disease with GBA1 variants is characterized by earlier onset, a tendency toward faster cognitive decline, and an increased risk of progression to dementia with Lewy bodies. Genetic counseling and neuroprotective clinical trials in GBA1 variant carriers are actively under way.


4. General epidemiology

Parkinson disease is the second most common neurodegenerative disease after Alzheimer disease. Worldwide prevalence is about 150–200/100,000, rising to about 1–2% at age 60 or older and about 3–5% at age 80 or older. The number of patients worldwide is estimated at more than about 10 million, and is predicted to more than double by 2040 due to population aging. Annual incidence is about 8–18/100,000. Sex differences: men have about 1.5 times higher incidence than women, but the reason is unclear (an estrogen protective effect, differences in smoking, etc. have been proposed). Racial differences: higher prevalence has been reported in white people of European descent than in people of Asian and African descent, but differences in diagnosis may play a role.

Epidemiology in Korea: according to National Health Insurance data, the prevalence of Parkinson disease in Korea is about 200/100,000 (age 60 or older), and the number of patients continues to rise with population aging. Based on Health Insurance Review & Assessment Service (HIRA) data, about 120,000 registered patients with Parkinson disease were reported as of 2022. About 10,000-odd patients are newly added each year to Special Copayment Reduction (V124) registration.


5. Pathophysiology

The pathophysiology of Parkinson disease is understood on multiple levels.

Loss of dopaminergic neurons in the substantia nigra

Dopaminergic neurons of the substantia nigra pars compacta (SNc) in the midbrain are selectively lost. By the time symptoms appear, about 50–70% of nigral dopaminergic cells have already been lost. Reduced dopamine in the striatum → imbalance of the direct and indirect pathways of the basal ganglia → excessive inhibition of the motor cortex → slowness of movement, rigidity and tremor.

Alpha-synuclein aggregation and Lewy bodies

Misfolding of alpha-synuclein protein → aggregation in the sequence oligomers, protofibrils, fibrils → formation of Lewy bodies and Lewy neurites within dopaminergic neurons. Oligomeric alpha-synuclein exerts neurotoxicity through cell membrane disruption, mitochondrial dysfunction and impaired synaptic function. Alpha-synuclein pathology spreads from cell to cell in a prion-like manner.

Mitochondrial dysfunction and oxidative stress

As the mechanisms of the PINK1·PRKN genes show, abnormalities of mitochondrial quality control (mitophagy) are important in the development of Parkinson disease. Reduced complex I function → excessive production of ROS (reactive oxygen species) → oxidative stress → apoptosis of dopaminergic neurons. Dopamine itself generates toxic intermediates (dopamine quinone) during oxidation, contributing to nigral selectivity.

Braak pathological stages

The 6-stage progression of Parkinson pathology proposed by Braak and colleagues: stages 1–2 (lower brainstem, olfactory prodrome): loss of smell, constipation, REM sleep behavior disorder → stages 3–4 (substantia nigra, deep cerebrum): onset of motor symptoms → stages 5–6 (cortex): cognitive decline and dementia. This concept provides the theoretical basis for the importance of prodromal symptoms and for the gut-brain axis hypothesis.


6. Symptoms

The clinical symptoms of Parkinson disease are divided into motor and non-motor symptoms. Non-motor symptoms may appear years before motor symptoms.

Core motor symptoms (TRAP)

T (Tremor): mainly resting tremor, typically a "pill-rolling" pattern of the hand at a frequency of 4~6 Hz. It is prominent at rest rather than as an intention tremor and decreases with voluntary movement. It occurs in about 70% and begins unilaterally. R (Rigidity): resistance in all directions to passive joint movement, characterized by a "lead pipe" pattern or a "cogwheel" pattern (when accompanied by tremor). A (Akinesia/Bradykinesia): marked slowness in initiating and executing voluntary movement. Micrographia in handwriting, reduced stride length, reduced facial expression (masked face), hypophonia and reduced blinking appear. P (Postural instability): impaired postural reflexes increase the risk of falls. It generally appears late in the course of the disease.

Non-motor symptoms

Loss of smell (about 90%): the most common prodromal symptom, appearing years before motor symptoms. Sleep disorders: REM sleep behavior disorder (RBD, acting out dreams), insomnia, daytime sleepiness. Autonomic dysfunction: constipation (most common, appearing decades earlier), orthostatic hypotension, bladder dysfunction, erectile dysfunction, excess sebum. Neuropsychiatric symptoms: depression and anxiety (about 40%), cognitive decline (mild cognitive impairment and Parkinson disease dementia). Skin: sebum hypersecretion (oily face). Sensory: pain, restless legs syndrome.


7. Signs

On physical examination, resting tremor (about 70%) is the most striking finding. It becomes more pronounced with voluntary movement (contralateral movement such as repeated fist clenching). Cogwheel rigidity appears as a characteristic intermittent resistance during passive joint movement. Bradykinesia is identified as decreasing amplitude and slowing speed in repetitive movements such as finger tapping, repeated hand opening and closing, and foot tapping. Masked facies: reduced spontaneous facial expression, reduced blinking. Festinating gait: short, rapid steps, reduced arm swing, forward-stooped posture. Myerson's sign (blinking persists when the area between the eyes is tapped lightly) is positive in Parkinson disease. Orthostatic hypotension (a systolic drop of 20 mmHg or more): reflects autonomic dysfunction. DAT-SPECT imaging shows a striatal dopamine transporter deficit (useful for differentiating Parkinson disease from essential tremor).


8. Screening

Screening of the general population is currently not recommended. Surveillance for prodromal symptoms in high-risk groups is being carried out at the clinical research stage. Screening for prodromal symptoms: loss of smell (UPSIT, Brief Smell Identification Test), REM sleep behavior disorder (bed partner interview or polysomnography), constipation (no bowel movement for 3 days or more) and depression are recognized as prodromal symptoms of Parkinson disease. When these symptoms occur in combination, the person is classified as being at high risk of Parkinson disease and neurological follow-up is recommended. Genetic high-risk group: prospective clinical follow-up is recommended in carriers of LRRK2 G2019S or GBA1 variants (LRRK2 cohort, GBA1 cohort studies), and some clinical trials are applying neuroprotective treatments.


9. Diagnosis

Clinical diagnosis is the standard for Parkinson disease. The 2015 Movement Disorder Society (MDS) clinical diagnostic criteria are the current standard. Essential criterion: parkinsonism — bradykinesia must be present, accompanied by at least one of resting tremor or rigidity. Supportive criteria: include a clear response to levodopa, levodopa-induced dyskinesia, resting tremor of a limb, loss of smell, and cardiac sympathetic denervation (abnormal MIBG myocardial scintigraphy). Absolute exclusion criteria: cerebellar signs, downward vertical gaze palsy (suspected PSP), severe autonomic failure early in the course (suspected MSA), parkinsonism due to a specific causative drug, hydrocephalus, etc. DAT-SPECT (dopamine transporter single-photon emission computed tomography) confirms a striatal dopamine deficit and is useful for differentiating parkinsonism from essential tremor and other conditions. Brain MRI is used to differentiate structural causes. Severity is quantified with the MDS-UPDRS (Unified Parkinson's Disease Rating Scale).


10. Treatment

Treatment of Parkinson disease is mainly symptomatic; neuroprotective treatment has not yet been clinically established.

Dopamine replacement therapy

Levodopa/carbidopa: the most effective treatment for Parkinson disease to date. Levodopa is converted to dopamine in the brain, and carbidopa inhibits peripheral metabolism of levodopa to increase efficiency. Various formulations exist, including standard, extended-release, enteral (intrajejunal infusion) and inhaled forms. The main limitations of long-term use are wearing-off and dyskinesia. Dopamine agonists (DA): pramipexole, ropinirole and rotigotine (patch) are used as initial treatment or as adjuncts to levodopa. They have impulse control disorder side effects (pathological gambling, overeating, hypersexuality). MAO-B inhibitors: rasagiline, selegiline and safinamide relieve symptoms by inhibiting dopamine breakdown. COMT inhibitors: entacapone and opicapone further inhibit the peripheral metabolism of levodopa, reducing wearing-off.

Deep brain stimulation (DBS)

Electrodes are implanted in the subthalamic nucleus (STN) or globus pallidus internus (GPi), and high-frequency electrical stimulation modulates the abnormal basal ganglia circuitry. It is indicated in patients with mid-stage Parkinson's disease who respond well to levodopa but have severe wearing-off and dyskinesia. Dyskinesia and motor fluctuations improve markedly for about 3–5 years after surgery. Indications are limited in cognitive decline, severe autonomic failure, and atypical parkinsonism.

Non-pharmacological treatment

Physical therapy (balance training, gait correction), occupational therapy (training in activities of daily living), and speech therapy (swallowing and voice rehabilitation) are provided in parallel at all stages. Studies suggest that exercise (especially aerobic exercise, tai chi, boxing, etc.) is effective for symptom improvement and neuroprotection.


11. Prognosis

Parkinson's disease is a slowly progressive chronic neurodegenerative disease. The rate of progression varies greatly between individuals: some follow a relatively mild course for decades, while others progress rapidly. In the first several years after diagnosis there is a "honeymoon period" during which symptoms are well controlled with levodopa. After about 5 years, wearing-off (loss of drug effect) and dyskinesia begin to appear. On average, dependence on walking aids (walker, wheelchair) appears 10–15 years after diagnosis. Falls and pneumonia are the main causes of death. Non-motor symptoms (Parkinson's disease dementia, severe autonomic failure) have a decisive impact on quality of life and survival. Parkinson's disease dementia develops in more than half of patients within about 15–20 years after diagnosis. Life expectancy is slightly shorter than that of the general population (1–2 years), but with appropriate treatment and rehabilitation a near-normal lifespan is possible.


12. Prevention

Complete primary prevention of Parkinson's disease is currently not possible. However, risk factor management and lifestyle modification may have some preventive effect. Minimizing exposure to pesticides and insecticides: wearing appropriate protective equipment among agricultural workers, and using organic pest control methods. Regular aerobic exercise: moderate-intensity exercise 3–5 or more times per week is epidemiologically associated with a lower risk of Parkinson's disease, and a neuroprotective effect has been suggested in basic research. Moderate caffeine intake (2–3 cups of coffee/day) is epidemiologically associated with a protective effect. Management of genetically high-risk groups (LRRK2 G2019S, GBA1 variant carriers): regular neurological follow-up, monitoring for prodromal symptoms, and participation in clinical trials. Neuroprotective clinical trials of agents such as ambroxol (a GBA1 protein stabilizer) are under way in GBA1 variant carriers. Prevention of head trauma (wearing helmets, fall prevention) is also recommended.


13. References

  1. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015;30(12):1591-1601. DOI: 10.1002/mds.26424. PMID: 26474316.
  2. Hornykiewicz O. Dopamine (3-hydroxytyramine) and brain function. Pharmacol Rev. 1966;18(2):925-964. PMID: 4876231.
  3. Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24(2):197-211. DOI: 10.1016/s0197-4580(02)00065-9. PMID: 12498954.
  4. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997;276(5321):2045-2047. DOI: 10.1126/science.276.5321.2045. PMID: 9197268.
  5. GBD 2016 Parkinson's Disease Collaborators. Global, regional, and national burden of Parkinson's disease, 1990–2016. Lancet Neurol. 2018;17(11):939-953. DOI: 10.1016/S1474-4422(18)30295-3. PMID: 30287051.
  6. Dorsey ER, Bloem BR. The Parkinson Pandemic—A call to action. JAMA Neurol. 2018;75(1):9-10. DOI: 10.1001/jamaneurol.2017.3299. PMID: 29131880.
  7. Schrag A, Horsfall L, Walters K, Noyce A, Petersen I. Prediagnostic presentations of Parkinson's disease in primary care. Lancet Neurol. 2015;14(1):57-64. DOI: 10.1016/S1474-4422(14)70287-X. PMID: 25435387.
  8. Marek K, Jennings D, Lasch S, et al. The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol. 2011;95(4):629-635. DOI: 10.1016/j.pneurobio.2011.09.005. PMID: 21930184.
  9. Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. Nat Rev Dis Primers. 2017;3:17013. DOI: 10.1038/nrdp.2017.13. PMID: 28332488.
  10. Nalls MA, Blauwendraat C, Vallerga CL, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease. Lancet Neurol. 2019;18(12):1091-1102. DOI: 10.1016/S1474-4422(19)30320-5. PMID: 31701892.